1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,080 | 3,340 | 10.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE SUPPLEMENTAL NEW DRUG APPLICATION FOR TORIPALIMAB AS THE FIRST-LINE TREATMENT OF HER2-EXPRESSING ... | - | HKEx | ||
| Fr | Junshi Biosciences Announces the Acceptance of the sNDA for Toripalimab as the 1st-line Treatment of HER2-expressing Urothelial Carcinoma | 286 | GlobeNewswire (Europe) | SHANGHAI, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 20.06. | JUNSHI BIO (01877): POLL RESULTS OF THE 2024 ANNUAL GENERAL MEETING | - | HKEx | ||
| 20.06. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON COMPLETION OF PLACING OF NEW H SHARES UNDER ... | 2 | HKEx | ||
| SHANGHAI JUNSHI BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 20.06. | JUNSHI BIO (01877): COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE | - | HKEx | ||
| 20.06. | JUNSHI BIO (01877): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 19.06. | JUNSHI BIO (01877): CHANGE OF BOOK CLOSURE PERIOD AND RECORD DATE | - | HKEx | ||
| 13.06. | JUNSHI BIO (01877): PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 11.06. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - JT118 RECEIVED THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION | 2 | HKEx | ||
| 05.06. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* INDICATIVE ANNOUNCEMENT ON THE CHANGE IN EQUITY OF THE SHAREHOLDERS ... | 1 | HKEx | ||
| 29.05. | JUNSHI BIO (01877): FORM OF PROXY FOR THE 2024 ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, 20 JUNE 2025 | 3 | HKEx | ||
| 29.05. | JUNSHI BIO (01877): 2024 ANNUAL REPORTS AND ACCOUNTS 2024 PROFIT DISTRIBUTION PLAN CREDIT LINES FROM FINANCIAL INSTITUTION(S) FOR 2025 DIRECTORS' AND ... | - | HKEx | ||
| 29.05. | JUNSHI BIO (01877): NOTICE OF THE 2024 ANNUAL GENERAL MEETING | 1 | HKEx | ||
| 29.05. | JUNSHI BIO (01877): CLOSURE OF REGISTER OF MEMBERS OF H SHARES | 1 | HKEx | ||
| 29.05. | JUNSHI BIO (01877): ANNOUNCEMENT - ADJUSTMENTS TO THE USE OF PROCEEDS FROM THE 2022 ISSUANCE OF A SHARES | - | HKEx | ||
| 27.05. | Junshi Biosciences Announces Ongericimab's sNDA Approval in China | 353 | GlobeNewswire (Europe) | SHANGHAI, May 27, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the... ► Artikel lesen | |
| 27.05. | JUNSHI BIO (01877): VOLUNTARY ANNOUNCEMENT - APPROVAL OF THE SUPPLEMENTAL NEW DRUG APPLICATION FOR ONGERICIMAB INJECTION | 3 | HKEx | ||
| 16.05. | JPMorgan raises Junshi Biosciences rating to neutral | 2 | Investing.com | ||
| 25.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2025 FIRST QUARTERLY REPORT | 3 | HKEx | ||
| 25.04. | JUNSHI BIO (01877): OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE PARTICIPATION IN THE 2024 ANNUAL RESULTS ... | - | HKEx |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,075 | -0,05 % | Qiagen NV-Aktie mit Kursgewinnen (43,155 €) | Im Plus liegt derzeit die Qiagen NV-Aktie . Der jüngste Kurs betrug 43,16 Euro. Im Wertpapierhandel hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,90 Prozent verteuert. Der Kurs des... ► Artikel lesen | |
| BEAM THERAPEUTICS | 17,620 | -1,34 % | Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD) | With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile... ► Artikel lesen | |
| JANUX THERAPEUTICS | 22,830 | +1,11 % | Janux Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| EVOTEC | 6,778 | +1,35 % | Aktien Frankfurt Ausblick: Leichte Entspannung nach US-Arbeitsmarktschock | FRANKFURT (dpa-AFX) - Nach einem von Konjunktursorgen getriebenen Rückschlag dürfte sich der deutsche Aktienmarkt am Montag zunächst leicht erholen. Der X-Dax signalisierte für den hiesigen Leitindex... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 46,240 | -2,69 % | Aktien New York: Erholungspfad wieder aufgenommen - Apple ziehen stark an | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch nach dem etwas schwächeren Vortag wieder den Weg nach oben eingeschlagen. Für Bewegung sorgten positiv aufgenommene Nachrichten zu Apple sowie Unternehmensberichte.... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 32,150 | -2,90 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
| COGENT BIOSCIENCES | 10,960 | +0,92 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| BIONTECH | 96,15 | +0,16 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen | |
| Y-MABS THERAPEUTICS | 8,520 | 0,00 % | Y-mAbs Therapeutics, Inc.: Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments | Reported Total Revenues of $19.5 million for the second quarter of 2025, exceeding the high end of the Company's guidance range of between $17 million and $19 millionSERB Pharmaceuticals to acquire... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 17,500 | -0,85 % | ARS Pharmaceuticals, Inc.: EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,525 | -1,34 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| ARCELLX | 70,53 | -0,87 % | Arcellx GAAP EPS of -$0.94 beats by $0.10, revenue of $7.55M misses by $6.37M | ||
| DAY ONE BIOPHARMACEUTICALS | 6,100 | +1,16 % | Day One Biopharmaceuticals outlines $140M-$150M 2025 OJEMDA revenue target as new patient scripts accelerate | ||
| AMYLYX PHARMACEUTICALS | 7,640 | -2,55 % | Amylyx anticipates Avexitide Phase III data in H1 2026 while expanding rare disease pipeline | ||
| SUMMIT THERAPEUTICS | 28,675 | +2,16 % | Summit Therapeutics: Ivonescimab zeigt überlegenes progressionsfreies Überleben gegenüber Pembrolizumab |
SHANGHAI JUNSHI BIOSCIENCES CO LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +6,90 % bei einem Aktienkurs von 3,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHANGHAI JUNSHI BIOSCIENCES CO LTD finden Sie auf Wallstreet Online.